Phase III Study of CG100649 in Osteoarthritis Patients
A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients
Sponsor: CrystalGenomics, Inc.
This PHASE3 trial investigates Localized Primary Osteoarthritis of Hip and Localized Primary Osteoarthritis of Knee and is currently completed. CrystalGenomics, Inc. leads this study, which shows 7 recorded versions since 2013 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jan 2021 — Mar 2023 [monthly]
Unknown Status PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Mar 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CrystalGenomics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .